ARIA News 6.16 08/29/2014 04:35:03 Ariad Pharmaceuticals (AR

New Post Public Reply Private Reply Replies (0) Message Board

Aug 29, 2014 at 5:35 AM

Ariad Pharmaceuticals (ARIA) 6.16 $ARIA

Ariad Pharmaceuticals Rises 4.50% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Aug 26, 4:26PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.12 to a high of $6.65. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $6.25 on volume of 14.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Why Ariad Pharmaceuticals (ARIA) Stock Is Up Today
at The Street - Tue Aug 26, 11:36AM CDT
Ariad Pharmaceuticals (ARIA) rose Tuesday as Roche's $8.3 billion acquisition of InterMune (ITMN) has led the biotech sector higher.

5 Stocks Insiders Love Right Now
at The Street - Thu Aug 21, 1:11PM CDT
Insiders at these companies have been scooping up shares of their own stock lately.

Look for Shares of Ariad Pharmaceuticals to Potentially Pullback after Yesterday's 2.90% Rise
Comtex SmarTrend(R) - Tue Aug 12, 5:00PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $5.48 to a high of $5.79. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $5.63 on volume of 5.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

ARIAD Falls on Wider-than-Expected Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 11:21AM CDT
ARIAD (ARIA) reported a loss of 30 cents per share in the second quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 27 cents.

11.6% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA)
Comtex SmarTrend(R) - Fri Aug 08, 10:00AM CDT
SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 8th, 2014 at $6.07. In approximately 1 month, Ariad Pharmaceuticals has returned 11.62% as of today's recent price of $5.36.

ARIAD Reports Second Quarter 2014 Financial Results and Development Progress
Business Wire - Wed Aug 06, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter of 2014, including revenue from sales of Iclusig(R) (ponatinib). The Company also provided an update on corporate developments.

Will GW Pharmaceuticals (GWPH) Miss this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 3:45PM CDT
GW Pharmaceuticals (GWPH) is scheduled to report third-quarter fiscal 2014 results on Aug 6.

Should You Sell Ariad Pharmaceuticals (ARIA) Before Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 7:48AM CDT
Ariad Pharmaceuticals (ARIA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company looks set to produce a positive earnings surprise and outperform the market.

ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel
Business Wire - Tue Aug 05, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that ARIAD has granted Medison exclusive rights to commercialize Iclusig(R) (ponatinib) in Israel in patients with Philadelphia-positive (Ph+) leukemias.

The Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata Therapeutics
PR Newswire - Fri Aug 01, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA-Free Report), ImmunoGen, Inc. (Nasdaq:IMGN-Free Report) and Durata Therapeutics, Inc. (Nasdaq

RTX-Free Report).

Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma
PR Newswire - Fri Aug 01, 8:00AM CDT
On Thursday, July 31, 2014, the NASDAQ Composite ended at 4,369.77, down 2.09%, the Dow Jones Industrial Average finished the day 1.88% lower at 16,563.30, and the S&P 500 closed at 1,930.67, down 2.00%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 704.37, down 2.03%, and the index has declined 0.02% in the last one month. Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation(NASDAQ: GERN), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research on these five companies can be accessed at:

3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.

3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Jul 30, 5:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.

Storm The Castle: ARIAD Pharmaceuticals (ARIA)
at The Street - Tue Jul 29, 1:35PM CDT
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate

Nasdaq stocks posting largest percentage increases
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Most active Nasdaq-traded stocks
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:

3 Huge Stocks to Trade (or Not)
at The Street - Thu Jul 24, 2:09PM CDT
Here's how to trade some of the most active stocks on the market today.

Ariad Pharmaceuticals (ARIA) Worth Watching: Stock Gains 15.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:25AM CDT
Ariad Pharmaceuticals (ARIA) was a big mover last session, with shares rising over 15% on the day.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan Activewear Faces Securities Fraud Lawsuit: Key Actions

Investors Reeling from Gildan's Stock Plunge Here we go again, folks. Gildan Activewear is making headlines, and not for reasons any stockholder wants to see. The company's embroiled in a securities fraud class action lawsuit, and if you're holding onto any NYSE:GIL shares, it's time to pay attention. This isn't some minor hiccup, either; there's heavy accusations on the...

Siemens Set to Acquire Lauterbach in Strategic Move

Siemens Seizing New Opportunities with Lauterbach Acquisition Bam! Siemens is on the move, folks, snapping up Lauterbach to bolster its semiconductor design arsenal. Now, if you’ve got your eyes glued to innovation in chip design, like yours truly, then strap in because this merger is more than just a footnote on some dusty tech page. It's a game-changer when it comes...

JD Technologies and GBG Marketing Join Forces

New Collaboration in Industrial Marketing Now here’s a twist in the industrial marketing game: JD Technologies Global (JDTG) and GBG Marketing have decided to buddy up. On this wild ride of market competition, these two are tightening their grip with a strategic partnership announced on a not-so-chill November day in Palm Coast, Florida. JDTG is sticking to its guns on...

Pyxus Starts Exchange Offer for 8.50% Notes, 2027

Pyxus Restructures Via Exchange Offer Pites, it's time for Pyxus International to show its hand. The global agricultural player has rolled up its sleeves, kicking off an exchange offer for its 8.50% notes maturing in 2027. With $148.3 million hanging in the balance, this move is their shot at managing debt and keeping things steady—like a farmer making sure the...

Bakersfield Sees Spike in Crashes Post Time Change

Evening Darkness and Safety Concerns Folks, it seems Bakersfield streets transform into a battlefield once the clock falls back. With darkness creeping in earlier, those evening hours right after the time change see a sobering uptick in accidents. According to an analysis by Chain | Cohn | Clark, pedestrian and bicyclist crashes from 5 to 7 p.m. double. It's not just...

Houston's Health Museum Introduces 'Sensing Sound' Exhibit

Sound Takes Center Stage in Houston There's a new kind of hush in Houston and it ain't just the Texas sun setting low. Come November 21, The Health Museum throws its doors wide open with an exhibition that'll have visitors hearing sound like they've never imagined before. Now, I don't want to sound like a broken record, but this type of exhibition—the Sensing...

Maternal Role in Type 1 Diabetes: A Non-Genetic Angle

Unveiling the Maternal Puzzle in Type 1 Diabetes So here's a stumper: how come kids of moms with type 1 diabetes dodge the disease more than kids of dads with it? Simple genes don't account for it, says a study from University of Colorado Anschutz. With nearly 7,000 kids in this research, you'd think they'd find a genetic smoking gun. Nope. It's pointing to something else...

Durability Over Comfort: Vibram's Global Footwear Shift

Durability Takes Center Stage in Footwear Choices Out with the fleeting, in with the durable! Vibram, that powerhouse in performance soles known for its little yellow octagon logo, is grabbing durability by the laces and pushing it to the forefront of the footwear game. With a freshly minted global survey shaking things up, turns out almost 8 in 10 of us aren't just...

AptarGroup Faces Investigation: Shareholder Stakes High

AptarGroup Directors Under Investigation Every seasoned investor knows the market isn’t just sunshine and rainbows. Lately, the storm clouds have gathered over AptarGroup, Inc. (NYSE: ATR). Out of nowhere comes Purcell & Lefkowitz LLP, announcing a shareholder investigation that sends shivers down the spines of those who've put their money on this packaging...

PMET's Lithium-Tantalum Study Ups Stakes in Québec Project

Elevated Ambitions in Québec: PMET's Lithium-Tantalum Leap PMET Resources just handed us an intriguing update on their Shaakichiuwaanaan project up in Québec. They're reshaping the roadmap to crank out both lithium and tantalum more efficiently than a bear on a honeycomb. The revised feasibility study has put to paper numbers that have optimists—and skeptics...